for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Guardant Health Inc

GH.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
25.94
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
93.91
Market Cap (MIL)
6,887.06
Forward P/E
-83.34
Dividend (Yield %)
--

Latest Developments

More

Guardant Health Posts Q3 Loss Per Share Of $0.14

Guardant Health Q2 Loss Per Share $0.13

Guardant Health Announces Pricing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Guardant Health Inc

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.

Industry

Biotechnology & Drugs

Contact Info

505 Penobscot Dr

+1.650.2907575

http://www.guardanthealth.com

Executive Leadership

AmirAli Talasaz

Chairman of the Board, President, Chief Operating Officer

Helmy A. Eltoukhy

Chief Executive Officer, Director

Derek Bertocci

Chief Financial Officer

Richard B. Lanman

Chief Medical Officer

Michael J. Wiley

Chief Legal Officer

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019(E)

0.2K
EPS (USD)

2018

-2.800

2019(E)

-0.880
Price To Earnings (TTM)
--
Price To Sales (TTM)
37.36
Price To Book (MRQ)
8.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.02
LT Debt To Equity (MRQ)
0.01
Return on Investment (TTM)
-12.86
Return on Equity (TTM)
-10.98

Latest News

Latest News

SoftBank's Vision Fund to borrow $4 billion against stakes in Uber and two others: FT

SoftBank's Vision Fund is looking to borrow $4 billion against its stakes in Uber Technologies Inc, soon-to-go-public Slack Technologies Inc, and blood-testing company Guardant Health Inc, the Financial Times reported, citing people directly involved in the deal.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up